Squamous Cell Carcinoma of the Lung Pipeline Insight

DelveInsight’s, “Squamous Cell Carcinoma of the Lung Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Squamous Cell Carcinoma of the Lung pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

 

Squamous Cell Carcinoma of the Lung: Understanding

Squamous Cell Carcinoma of the Lung: Overview

Squamous cell carcinoma of the lung (LUSC or lung SCC) is a major histological subtype of non-small cell lung cancer (NSCLC), accounting for approximately 20–30% of all lung cancers. It originates from the squamous epithelial cells lining the central bronchi and is strongly associated with long-term tobacco smoking, although occupational exposures such as asbestos, radon, and heavy metals also contribute to disease risk. Lung SCC typically arises in the central airways and has distinct pathological and molecular characteristics compared with lung adenocarcinoma.

 

Patients with early-stage lung SCC are frequently asymptomatic, resulting in delayed diagnosis. As the tumor enlarges, common manifestations include persistent cough, hemoptysis, dyspnea, chest pain, wheezing, hoarseness, recurrent respiratory infections, fatigue, anorexia, and unexplained weight loss. Advanced disease may present with symptoms related to metastatic spread, including bone pain, neurological deficits, headaches, seizures, or spinal cord compression. The clinical presentation largely depends on tumor size, airway obstruction, and metastatic involvement.

 

The pathogenesis of lung SCC begins with chronic exposure to tobacco carcinogens, leading to squamous metaplasia, epithelial dysplasia, carcinoma in situ, and ultimately invasive carcinoma. Molecular alterations commonly involve TP53 mutations, CDKN2A inactivation, SOX2 amplification, FGFR1 amplification, PI3K pathway abnormalities, and KEAP1/NFE2L2 mutations, which promote uncontrolled cellular proliferation, impaired apoptosis, genomic instability, and resistance to oxidative stress. Histologically, tumors are characterized by keratinization and intercellular bridges, with immune-histochemical markers such as p40 and p63 supporting diagnosis.

 

Diagnosis is established through a combination of clinical evaluation, contrast-enhanced chest CT, PET-CT for staging, bronchoscopy with tissue biopsy for centrally located tumors, and histopathological examination with immunohistochemistry. Molecular profiling and PD-L1 testing are increasingly performed to guide therapeutic decisions. Treatment depends on disease stage and includes surgical resection for early-stage disease, platinum-based chemotherapy, radiotherapy, immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors), and selected targeted therapies under investigation for advanced disease. Multidisciplinary management has substantially improved survival, particularly with the integration of immunotherapy into first-line treatment for advanced lung SCC.

 

"Squamous Cell Carcinoma of the Lung Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Squamous Cell Carcinoma of the Lung pipeline landscape is provided which includes the disease overview and Squamous Cell Carcinoma of the Lung treatment guidelines. The assessment part of the report embraces, in depth Squamous Cell Carcinoma of the Lung commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Squamous Cell Carcinoma of the Lung collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Squamous Cell Carcinoma Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Squamous Cell Carcinoma of the Lung R&D. The therapies under development are focused on novel approaches to treat/improve Squamous Cell Carcinoma of the Lung.

 

Squamous Cell Carcinoma of the Lung Emerging Drugs Chapters

This segment of the Squamous Cell Carcinoma of the Lung report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Squamous Cell Carcinoma of the Lung Emerging Drugs

HB0025: Huabo Biopharm

HB0025 is an investigational PD-L1/VEGF bispecific antibody developed by Shanghai Huaota Biopharmaceutical that simultaneously blocks the PD-L1 immune checkpoint pathway while inhibiting VEGF-mediated tumor angiogenesis, thereby enhancing antitumor immune responses and suppressing tumor vascularization. In the ongoing Phase III trial, HB0025 is being evaluated in combination with paclitaxel and carboplatin versus pembrolizumab plus chemotherapy as a first-line treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).

 

HLX07: Shanghai Henlius Biotech

HLX07 is an investigational humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody developed by Shanghai Henlius that blocks EGFR-mediated signaling, thereby inhibiting tumor cell proliferation and survival. In the ongoing Phase II/III trial, HLX07 is being evaluated in combination with the PD-1 inhibitor serplulimab and platinum-based chemotherapy (carboplatin plus paclitaxel or nab-paclitaxel) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sqNSCLC). The study aims to determine whether adding HLX07 to standard immunochemotherapy improves objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with placebo-based regimens.

 

Raludotatug deruxtecan: Daiichi Sankyo/Merck & Co

Raludotatug deruxtecan (R-DXd; MK-5909; DS-6000a) is an investigational cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC) that combines a humanized anti-CDH6 monoclonal antibody with the deruxtecan (DXd) topoisomerase I inhibitor payload via a cleavable linker. Upon binding to CDH6-expressing tumor cells, the ADC is internalized and releases the cytotoxic DXd payload, inducing DNA damage and tumor cell death while also exerting a bystander antitumor effect. In the ongoing (KEYMAKER-U01) Phase II study, R-DXd is being evaluated as monotherapy against docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer (sqNSCLC) to assess its efficacy, safety, objective response rate, progression-free survival, and overall survival.

EVM14: Everest Medicines

EVM14 is an investigational off-the-shelf mRNA cancer vaccine developed by Everest Medicines that encodes multiple tumor-associated antigens (TAAs) using a lipid nanoparticle (LNP) delivery platform. Following intramuscular administration, the mRNA is taken up by antigen-presenting cells, resulting in antigen expression and activation of tumor-specific CD4? and CD8? T-cell immune responses against cancer cells. In the Phase Ia trial, EVM14 is being evaluated in combination with ivonescimab for patients with PD-L1-positive, locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC) to assess its safety, tolerability, immunogenicity, and preliminary antitumor efficacy.

C-CAR031: AbelZeta Pharma/AstraZeneca

C-CAR031 (also known as AZD7003) is an investigational autologous, GPC3-targeted armored chimeric antigen receptor T-cell (CAR-T) therapy designed to treat GPC3-positive solid tumors, including squamous non-small cell lung cancer (sqNSCLC). The therapy incorporates a dominant-negative TGF-ß receptor II (dnTGFßRII) to overcome the immunosuppressive tumor microenvironment and enhance CAR-T cell persistence and antitumor activity. In the ongoing Phase I trial, C-CAR031 is being evaluated in patients with advanced or metastatic GPC3-positive squamous cell lung cancer who have progressed after prior platinum-based chemotherapy and immune checkpoint inhibitor therapy. The study is assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor efficacy of escalating doses of C-CAR031 in this heavily pretreated patient population.

Further product details are provided in the report……..

Squamous Cell Carcinoma of the Lung Therapeutic Assessment

This segment of the report provides insights about the different Squamous Cell Carcinoma of the Lung drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Squamous Cell Carcinoma of the Lung

There are approx. 75+ key companies which are developing the therapies for Squamous Cell Carcinoma of the Lung. The companies which have their Squamous Cell Carcinoma of the Lung drug candidates in the most advanced stage, i.e. Phase III include, Huabo Biopharm.

Squamous Cell Carcinoma Clinical Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Squamous Cell Carcinoma Drugs Route of Administration

Squamous Cell Carcinoma of the Lung pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Squamous Cell Carcinoma Drugs Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Squamous Cell Carcinoma Pipeline Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Squamous Cell Carcinoma of the Lung Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Squamous Cell Carcinoma of the Lung therapeutic drugs key players involved in developing key drugs.

Squamous Cell Carcinoma Cinical Trials Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Squamous Cell Carcinoma of the Lung drugs.

Squamous Cell Carcinoma of the Lung Report Insights

• Squamous Cell Carcinoma of the Lung Pipeline Analysis
• Squamous Cell Carcinoma Therapeutic Assessment
• Squamous Cell Carcinoma Unmet Needs
• Impact of Squamous Cell Carcinoma Drugs

Squamous Cell Carcinoma of the Lung Report Assessment

• Squamous Cell Carcinoma Pipeline Product Profiles
• Squamous Cell Carcinoma Therapeutic Assessment
• Squamous Cell Carcinoma Pipeline Assessment
• Inactive Squamous Cell Carcinoma drugs assessment
• Squamous Cell Carcinoma Unmet Needs

Key Questions Answered in the Squamous Cell Carcinoma Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Squamous Cell Carcinoma of the Lung drugs?
• How many Squamous Cell Carcinoma of the Lung drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Squamous Cell Carcinoma of the Lung?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Squamous Cell Carcinoma of the Lung therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Squamous Cell Carcinoma of the Lung and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Squamous Cell Carcinoma Companies

• Huabo Biopharm
• Shanghai Henlius Biotech
• Daiichi Sankyo
• Merck & Co
• Everest Medicines
• AbelZeta Pharma
• AstraZeneca
• Shanghai JMT-Bio Inc.
• Zenith Epigenetics
• EvolveImmune United, Inc
• Bicara Therapeutics
• AbbVie
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Eikon Therapeutics
• RemeGen Co., Ltd.
• Zymeworks
• Nuvectis Pharma, Inc.
• Zelluna Immunotherapy AS
• Volastra Therapeutics, Inc.
• Sichuan Baili Pharmaceutical Co., Ltd.
• Sotio Biotech Inc.

Key Squamous Cell Carcinoma Pipeline Products

• HB0025
• HLX07
• Raludotatug deruxtecan
• EVM14
• C-CAR031
• JMT101
• ZEN003694
• EVOLVE104
• BCA101
• ABBV-711
• HDM2020
• EIK1001
• RC148
• ZW251
• NXP900
• ZI-MA4-1
• VLS-1488
• SI-B001
• BOXR1030